Congenital erythrocytoses represent a heterogenous group of rare defects of erythropoiesis characterized by elevated erythrocyte mass. We performed molecular-genetic analysis of 21 Czech patients with congenital erythrocytosis and assessed the mutual link between chronic erythrocyte overproduction and iron homoeostasis. Causative mutations in erythropoietin receptor (EPOR), hypoxia-inducible factor 2 alpha (HIF2A) or Von Hippel-Lindau (VHL) genes were detected in nine patients, including a novel p.A421Cfs*4 EPOR and a homozygous intronic c.340+770T>C VHL mutation. The association and possible cooperation of five identified missense germline EPOR or Janus kinase 2 (JAK2) variants with other genetic/non-genetic factors in erythrocytosis manifestation may involve variants of Piezo-type mechanosensitive ion channel component 1 (PIEZO1) or Ten-eleven translocation 2 (TET2), but this requires further research. In two families, hepcidin levels appeared to prevent or promote phenotypic expression of the disease. No major contribution of heterozygous haemochromatosis gene (HFE) mutations to the erythrocytic phenotype or hepcidin levels was observed in our cohort. VHL- and HIF2A-mutant erythrocytosis showed increased erythroferrone and suppressed hepcidin, whereas no overproduction of erythroferrone was detected in other patients regardless of molecular defect, age or therapy. Understanding the interplay between iron metabolism and erythropoiesis in different subgroups of congenital erythrocytosis may improve current treatment options.

Department of Biology Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Department of Haemato Oncology University Hospital Olomouc Olomouc Czech Republic

Department of Immunology Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Department of Paediatrics Faculty of Health Studies J E Purkyne University Usti nad Labem Czech Republic

Department of Paediatrics Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Olomouc Czech Republic

See more in PubMed

Prchal JT. Primary and Secondary Erythrocytoses/Polycythemias. Chap. 58. In: Kaushansky K, Lichtman MA, Prchal JT, Levi M, Burns LJ, Linch DC, editors. Williams hematology. 10th ed. New York: McGraw Hill; 2021. p. 941-60.

Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32(4):614-21.

Gangat N, Szuber N, Pardanani A, Tefferi A. JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views. Leukemia. 2021;35(8):2166-81.

Kapralova K, Horvathova M, Pecquet C, Fialova Kucerova J, Pospisilova D, Leroy E, et al. Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia. Blood. 2016;128(10):1418-23.

Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, et al. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 2019;125(11):1855-66.

Rabadan Moraes G, Pasquier F, Marzac C, Deconinck E, Damanti CC, Leroy G, et al. An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms. Br J Haematol. 2022;198(1):131-6.

Faucherre A, Kissa K, Nargeot J, Mangoni ME, Jopling C. Piezo1 plays a role in erythrocyte volume homeostasis. Haematologica. 2014;99(1):70-5.

Knight T, Zaidi AU, Wu S, Gadgeel M, Buck S, Ravindranath Y. Mild erythrocytosis as a presenting manifestation of PIEZO1 associated erythrocyte volume disorders. Pediatr Hematol Oncol. 2019;36(5):317-26.

Ma S, Dubin AE, Zhang Y, Mousavi SAR, Wang Y, Coombs AM, et al. A role of PIEZO1 in iron metabolism in mice and humans. Cell. 2021;184(4):969-82.e13.

Oskarsson GR, Oddsson A, Magnusson MK, Kristjansson RP, Halldorsson GH, Ferkingstad E, et al. Predicted loss and gain of function mutations in ACO1 are associated with erythropoiesis. Commun Biol. 2020;3(1):189.

Biagetti G, Catherwood M, Robson N, Bertozzi I, Cosi E, McMullin MF, et al. HFE mutations in idiopathic erythrocytosis. Br J Haematol. 2018;181(2):270-2.

Burlet B, Bourgeois V, Buriller C, Aral B, Airaud F, Garrec C, et al. High HFE mutation incidence in idiopathic erythrocytosis. Br J Haematol. 2019;185(4):794-5.

Nemeth E, Ganz T. Hepcidin and iron in health and disease. Annu Rev Med. 2023;74:261-77.

Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-84.

Stetka J, Usart M, Kubovcakova L, Rai S, Nageswara Rao T, Sutter J, et al. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023;141(17): 2127-40.

Zadrazil J, Horak P, Horcicka V, Zahalkova J, Strebl P, Hruby M. Endogenous erythropoietin levels and anemia in long-term renal transplant recipients. Kidney Blood Press Res. 2007;30(2):108-16.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.

Cario H, McMullin MF, Bento C, Pospisilova D, Percy MJ, Hussein K, et al. Erythrocytosis in children and adolescents-classification, characterization, and consensus recommendations for the diagnostic approach. Pediatr Blood Cancer. 2013;60(11):1734-8.

Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood. 1997;90(5):2057-61.

Al-Sheikh M, Mazurier E, Gardie B, Casadevall N, Galactéros F, Goossens M, et al. A study of 36 unrelated cases with pure erythrocytosis revealed three new mutations in the erythropoietin receptor gene. Haematologica. 2008;93(7):1072-5.

Kralovics R, Prchal JT. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol. 2001;68(2):115-21.

Kralovics R, Sokol L, Broxson EH Jr, Prchal JT. The erythropoietin receptor gene is not linked with the polycythemia phenotype in a family with autosomal dominant primary polycythemia. Proc Assoc Am Physicians. 1997;109(6):580-5.

Le Couedic JP, Mitjavila MT, Villeval JL, Feger F, Gobert S, Mayeux P, et al. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood. 1996;87(4):1502-11.

Sokol L, Prchal JF, D'Andrea A, Rado TA, Prchal JT. Mutation in the negative regulatory element of the erythropoietin receptor gene in a case of sporadic primary polycythemia. Exp Hematol. 1994;22(5):447-53.

Gross M, Ben-Califa N, McMullin MF, Percy MJ, Bento C, Cario H, et al. Polycythaemia-inducing mutations in the erythropoietin receptor (EPOR): mechanism and function as elucidated by epidermal growth factor receptor-EPOR chimeras. Br J Haematol. 2014;165(4):519-28.

Padgett RA. New connections between splicing and human disease. Trends Genet. 2012;28(4):147-54.

Cazzola M, Rossi M, Malcovati L. Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood. 2013;121(2):260-9.

Percy MJ, Furlow PW, Lucas GS, Li X, Lappin TR, McMullin MF, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med. 2008;358(2):162-8.

Perrotta S, Stiehl DP, Punzo F, Scianguetta S, Borriello A, Bencivenga D, et al. Congenital erythrocytosis associated with gain-of-function HIF2A gene mutations and erythropoietin levels in the normal range. Haematologica. 2013;98(10):1624-32.

Gale DP, Harten SK, Reid CD, Tuddenham EG, Maxwell PH. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. Blood. 2008;112(3):919-21.

Lenglet M, Robriquet F, Schwarz K, Camps C, Couturier A, Hoogewijs D, et al. Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood. 2018;132(5):469-83.

Panovska-Stavridis I, Eftimov A, Ivanovski M, Pivkova-Veljanovska A, Cevreska L, Hermouet S, et al. Essential thrombocythemia associated with germline JAK2 G571S variant and somatic CALR type 1 mutation. Clin Lymphoma Myeloma Leuk. 2016;16(5):e55-7.

Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127(3):333-42.

Lin M, Nebral K, Gertzen CGW, Ganmore I, Haas OA, Bhatia S, et al. JAK2 p.G571S in B-cell precursor acute lymphoblastic leukemia: a synergizing germline susceptibility. Leukemia. 2019;33(9):2331-5.

Bellanné-Chantelot C, Rabadan Moraes G, Schmaltz-Panneau B, Marty C, Vainchenker W, Plo I. Germline genetic factors in the pathogenesis of myeloproliferative neoplasms. Blood Rev. 2020;42:100710.

Luque Paz D, Kralovics R, Skoda RC. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023;141(16):1909-21.

Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333(6047):1300-3.

Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062-7.

Kutny MA, Alonzo TA, Gerbing RB, Ho PA, Geraghty D, Lange B, et al. TET2 SNP rs2454206 (I1762V) correlates with improved survival in pediatric acute myelogenous leukemia, a report from the children's oncology group. Blood. 2010;116(21):949.

Li MJ, Yang YL, Lee NC, Jou ST, Lu MY, Chang HH, et al. Tet oncogene family member 2 gene alterations in childhood acute myeloid leukemia. J Formos Med Assoc. 2016;115(9):801-6.

Schwarz J, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7(8):575-6.

Wang R, Gao X, Yu L. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis. BMC Cancer. 2019;19(1):389.

Picard V, Guitton C, Thuret I, Rose C, Bendelac L, Ghazal K, et al. Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patients. Haematologica. 2019;104(8):1554-64.

Filser M, Giansily-Blaizot M, Grenier M, Monedero Alonso D, Bouyer G, Pérès L, et al. Increased incidence of germline PIEZO1 mutations in individuals with idiopathic erythrocytosis. Blood. 2021;137(13):1828-32.

Divoky V, Liu Z, Ryan TM, Prchal JF, Townes TM, Prchal JT. Mouse model of congenital polycythemia: homologous replacement of murine gene by mutant human erythropoietin receptor gene. Proc Natl Acad Sci USA. 2001;98(3):986-91.

Kralova B, Sochorcova L, Song J, Jahoda O, Hlusickova Kapralova K, Prchal JT, et al. Developmental changes in iron metabolism and erythropoiesis in mice with human gain-of-function erythropoietin receptor. Am J Hematol. 2022;97(10):1286-99.

Brugnara C. Reference values in infancy and childhood. In: Orkin SH, Fisher DE, Look AT, Lux SE, Ginsburg D, Nathan DG, editors. Nathan and Oski's hematology of infancy and childhood. 7th ed. Philadelphia: Saunders Elsevier; 2009. p. 1769-96.

Percy ML. Genetically heterogeneous origins of idiopathic erythrocytosis. Hematology. 2007;1:131-9.

Sokol L, Luhovy M, Guan Y, Prchal JF, Semenza GL, Prchal JT. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood. 1995;86(1):15-22.

Pasquier F, Marty C, Balligand T, Verdier F, Grosjean S, Gryshkova V, et al. New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis. Haematologica. 2018;103(4):575-86.

Filser M, Aral B, Airaud F, Chauveau A, Bruce A, Polfrit Y, et al. Low incidence of EPOR mutations in idiopathic erythrocytosis. Haematologica. 2021;106(1):299-301.

Bento C, Almeida H, Maia TM, Relvas L, Oliveira AC, Rossi C, et al. Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (where is/are the missing gene(s)?). Eur J Haematol. 2013;91(4):361-8.

Peroni E, Bertozzi I, Gherlinzoni F, Stefani PM, Lombardi A, Biagetti G, et al. Two novel missense mutations in EPOR gene causes erythrocytosis in two unrelated patients. Br J Haematol. 2018;180(6):908-11.

Tun PWW, Buka RJ, Graham J, Dyer P. Heterozygous, germline JAK2 E846D substitution as the cause of familial erythrocytosis. Br J Haematol. 2022;198(5):923-6.

Schulze S. Concomitant and noncanonical JAK2 and MPL mutations in JAK2 V617F- and MPL W515L-positive myelofibrosis. Genes Chromosomes Cancer. 2019;58(11):747-55.

Gordeuk VR, Miasnikova GY, Sergueeva AI, Niu X, Nouraie M, Okhotin DJ, et al. Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression. Blood. 2011;118(19):5278-82.

Díaz V, Gammella E, Recalcati S, Santambrogio P, Naldi AM, Vogel J, et al. Liver iron modulates hepcidin expression during chronically elevated erythropoiesis in mice. Hepatology. 2013;58(6):2122-32.

Kapralova K, Lanikova L, Lorenzo F, Song J, Horvathova M, Divoky V, et al. RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling. Blood. 2014;123(3):391-4.

Lakhal S, Schödel J, Townsend AR, Pugh CW, Ratcliffe PJ, Mole DR. Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis. J Biol Chem. 2011;286(6):4090-7.

McMahon S, Grondin F, McDonald PP, Richard DE, Dubois CM. Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem. 2005;280(8):6561-9.

Sonnweber T, Nachbaur D, Schroll A, Nairz M, Seifert M, Demetz E, et al. Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut. 2014;63(12):1951-9.

Song J, Kim SJ, Thiagarajan P, Prchal JT. Iron deficiency in polycythemia Vera increases HIF activity and transcription of prothrombotic genes. Blood. 2021;138(1):2549.

Gangaraju R, Song J, Kim SJ, Tashi T, Reeves BN, Sundar KM, et al. Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv. 2020;4(6):1115-30.

Camps C, Petousi N, Bento C, Cario H, Copley RR, McMullin MF, et al. Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations. Haematologica. 2016;101(11):1306-18.